Member Info for PL75

Yeah, absolutely, makes perfect sense, but it’s regulation. Just have to wait and see if their view stays the same after what will hopefully be stellar 2W and P2 results.

ODD is for unmet need.

Absolutely no problem. It's nailed on. 137p won't stand a chance

We've averaged about 10% a day over yesterday & today. Continuing that pace will mean ATHs in fewer than 20 market days. Easy!

It’s not GameStop. There’ll be no short squeeze. It won’t be killing them. Personally I don’t want heights paid in cash. We won’t reach ATHs in the next few months. I do agree that the remainder of the year will be good based on Chris’ promise to deliver.

B2, that’s where pre|CISION ADCs come in. It’s effectively a repeat of the affimers Vs antibodies slide of old, but CC is presenting it as a third product class. Might give an opportunity for BP to save some face. Keep their acquired ADCs and modify them. Otherwise, they’ve fat pockets, we’re pretty cheap at let’s say $10bn for the platform. They pretty much said at the AGM they’re planning for the long term but don’t realistically expect to get there. The exit plan is a sale once they’re tidied up as a Tx company and are further down the line with the trial.

I asked for the references:

The exact study I referred to is not specified in my previous response. However, there are several studies that have investigated the pharmacokinetics and tissue distribution of doxorubicin, including its concentration in tumors versus plasma.

One frequently referenced study is:

Matsumura, Y., & Maeda, H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Research, 46(12 Part 1), 6387-6392.

This seminal paper introduced the concept of the Enhanced Permeability and Retention (EPR) effect, which explains why macromolecules and nanoparticles, such as liposomal doxorubicin, accumulate in tumor tissues more than in normal tissues.

Another relevant study is:

Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003). Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. Clinical Pharmacokinetics, 42(5), 419-436.

This review discusses the distribution of pegylated liposomal doxorubicin (Doxil) in tumors and plasma, highlighting the higher concentration of the drug in tumors compared to plasma.

Not sure what prompt you used. Here’s what I got back:

“The ratio of doxorubicin concentration in the tumor microenvironment versus the plasma after 24 hours can vary depending on several factors, including the type of tumor, the method of administration, and the individual patient's physiology. However, research studies often provide some general insights into this ratio.

Studies have shown that doxorubicin tends to accumulate in the tumor tissue due to the enhanced permeability and retention (EPR) effect, which is characteristic of many solid tumors. This effect allows nanoparticles and macromolecules to preferentially accumulate in tumor tissue compared to normal tissues.

One study investigating the pharmacokinetics of doxorubicin found that after systemic administration, the concentration of doxorubicin in the tumor tissue could be several times higher than that in the plasma after 24 hours. Specifically, the tumor-to-plasma concentration ratio can range from approximately 5:1 to 20:1 depending on the tumor model and experimental conditions.

For a more precise ratio applicable to specific clinical or experimental settings, it would be necessary to consult detailed pharmacokinetic studies or clinical trial data involving doxorubicin administration in similar conditions.”

So 100:1 is a vast improvement. Chris explained clearly, it won’t become the SoC for all dox overnight, but it would become the SoC for their chosen indication if all goes well. Others will follow - but likely to be deals as deep pockets are needed

Thanks for posting, thanks to the attendees, thanks to the recorder. I thought it was excellent. A breath of fresh air compared to WaffAl’s rollocks. Chris said it, they’ll be a company that will set out clearly what they’re going to do and they’ll do it, if not they’ll tell us. That’s what I’ve been wanting since investing. Excellent Q&A, I’m not surprised to see a share price reaction.

Try reading the answer again.

What’s the problem. New range of Spanish metal ditectors being launched

What's the issue? New office in Spain, ran by the board ofnditectoros.

Easy - Flog ava3996, keep ava6k, pipeline of mad toxic stuff innit

*Cawfee

Chris is going to unveil her pipeline. How very uncouth

Eggy’s the trolling twat’s beloved Mongolian gamble has just had a raise at a whopping discount. Shame.

It’s not far off the equivalent of cohort 6 in terms of total dose, whacked in a shorter timeframe, still no DLTs. Incredible. Maybe squeeze in a short short study and try weekly for lolz

That is an excellent RNS. No negatives. All good. Tony gone. Trial progressing. Costs cut. All on track. No WaffAl. Nice one Chris.

Don’t worry Alan’s mansion is next door, he’ll be keeping it afloat. No doubt he’ll have set up an Abakta rejects WhatsApp group and that’ll be where they have their regular meet-ups chuckling about the time he chuckled and they both said they weren’t boosters to justify destroying shareholder value. They can’t wait for Tony to join them soon

Can't buy anything on HL right now